Tharimmune acquires global license and partners with intract pharma to develop an oral formulation of infliximab

Bridgewater, nj and london, uk / accesswire / september 16, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with intract pharma to exclusively license int-023/th023, an oral anti-tumor necrosis factor-alpha (tnf-Α) monoclonal antibody, infliximab. this strategic partnership aims to expand tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.
THAR Ratings Summary
THAR Quant Ranking